Following on from information provided to NICE by the company in May 2020 the appraisal of Pelareorep for treating relapsed or refractory multiple myeloma [ID1028] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1028 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 November 2022 | Following on from information provided to NICE by the company in May 2020 the appraisal of Pelareorep for treating relapsed or refractory multiple myeloma [ID1028] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 15 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2020 the appraisal of Pelareorep for treating relapsed or refractory multiple myeloma [ID1028] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 25 June 2020 | Company have advised this technology in no longer in development. |
| 25 June 2020 | Suspended. Topic is suspended |
For further information on our processes and methods, please see our CHTE processes and methods manual